source
- BridgeBio secures $1 billion in equity financing ahead of three upcoming drug launchesBridgeBio Pharma announced it has raised about $1 billion through a preferred equity transaction. The new capital will strengthen its balance sheet as the company prepares three potential drug lau…
- Merck ends Phase 2 trial of Alzheimer’s drug MK-1167 from partner NeuphoriaMerck announced it has terminated a mid-stage Phase 2 study of an experimental Alzheimer’s therapy. The drug, called MK-1167, is an oral candidate that was being developed in collaboration with bi…